Multiplex Analysis of Peripheral Blood in Cancer Patients Predicts Humoral and Cellular Responses to Sars-Cov-2 Vaccines
Maryam Kazerani(Cedars-Sinai Medical Center), Akil Merchant(University of Southern California), Inderjit Mehmi, Nathalie Huỳnh Châu Nguyễn(Cedars-Sinai Medical Center), Joslyn Foley(Cedars-Sinai Medical Center), V. Krishnan Ramanujan(Cedars-Sinai Medical Center), Jane C. Figueiredo(University of Southern California), Joseph Lownik(Cedars-Sinai Medical Center), Omid Hamid(Cedars-Sinai Medical Center), So Yung Choi(Cedars-Sinai Medical Center), Noah Merin(Cedars-Sinai Medical Center), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Larry Milshteyn(Cedars-Sinai Medical Center), Warren G. Tourtellotte(Cedars-Sinai Medical Center), Alexander M. Xu(Cedars-Sinai Medical Center), Simeon Mahov(Cedars-Sinai Medical Center), Justin Darrah(Cedars-Sinai Medical Center), Anton Villamejor(Cedars-Sinai Medical Center), Jun Gong(Cedars-Sinai Medical Center), Robert Vescio(Royal Adelaide Hospital), Alain C. Mita(Cedars-Sinai Medical Center), Ronald Paquette, Maimoona Nadri(Cedars-Sinai Medical Center)
Cited by 0
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k